Showing results (81-90 of 119) with videos related to

Sort By:
Pageof 12
BMC Cancer|December 10, 2017
Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancerYasuyuki Kawamoto, Yoshito Komatsu, Satoshi Yuki, et al.
European Journal of Cancer (Oxford, England : 1990)|July 25, 2021
Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trialTadamichi Denda, Atsuo Takashima, Makio Gamoh, et al.
International Journal of Cancer|August 14, 2024
A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801Hiroshi Nakatsumi, Yoshito Komatsu, Kazuaki Harada, et al.
Cancer Medicine|August 29, 2023
Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit studySatoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Clinical Colorectal Cancer|February 8, 2024
Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit StudySatoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 19, 2026
Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201)Kazuaki Harada, Shinya Kajiura, Kentaro Sawada, et al.
BMJ Open|May 9, 2022
Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancerShintaro Nakano, Yasuyuki Kawamoto, Satoshi Yuki, et al.
Targeted Oncology|May 20, 2026
Plasma Biomarkers Associated with Clinical Outcomes of FOLFIRI Plus Ramucirumab in RAS Wild-Type Metastatic Colorectal Cancer: The JACCRO CC-16AR TrialYu Sunakawa, Hisateru Yasui, Manabu Shiozawa, et al.
Cancer Science|February 6, 2021
Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancerShin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, et al.
JCO Precision Oncology|August 11, 2022
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2-Positive Esophagogastric and Gastric CancerKaori Hino, Tomohiro Nishina, Takeshi Kajiwara, et al.
Pageof 12